269 related articles for article (PubMed ID: 12513801)
61. Costimulatory molecules and autoimmune thyroid diseases.
Salmaso C; Olive D; Pesce G; Bagnasco M
Autoimmunity; 2002 May; 35(3):159-67. PubMed ID: 12389640
[TBL] [Abstract][Full Text] [Related]
62. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation.
Gonzalo JA; Delaney T; Corcoran J; Goodearl A; Gutierrez-Ramos JC; Coyle AJ
J Immunol; 2001 Jan; 166(1):1-5. PubMed ID: 11123268
[TBL] [Abstract][Full Text] [Related]
63. New protein steals the show as 'costimulator' of T cells.
Cohen J
Science; 1993 Nov; 262(5135):844-5. PubMed ID: 7694360
[No Abstract] [Full Text] [Related]
64. T-cell activation in autoimmune and inflammatory diseases.
Perkins DL
Curr Opin Nephrol Hypertens; 1998 May; 7(3):297-303. PubMed ID: 9617561
[TBL] [Abstract][Full Text] [Related]
65. Targeting the B7/CD28:CTLA-4 costimulatory system in CNS autoimmune disease.
Karandikar NJ; Vanderlugt CL; Bluestone JA; Miller SD
J Neuroimmunol; 1998 Aug; 89(1-2):10-8. PubMed ID: 9726820
[TBL] [Abstract][Full Text] [Related]
66. Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo.
Krummel MF; Sullivan TJ; Allison JP
Int Immunol; 1996 Apr; 8(4):519-23. PubMed ID: 8671638
[TBL] [Abstract][Full Text] [Related]
67. Expression and functional significance of an additional ligand for CTLA-4.
Lenschow DJ; Su GH; Zuckerman LA; Nabavi N; Jellis CL; Gray GS; Miller J; Bluestone JA
Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11054-8. PubMed ID: 7504292
[TBL] [Abstract][Full Text] [Related]
68. The ups and downs of T cell costimulation.
Jenkins MK
Immunity; 1994 Sep; 1(6):443-6. PubMed ID: 7534615
[No Abstract] [Full Text] [Related]
69. Co-stimulation in T cell responses.
Chambers CA; Allison JP
Curr Opin Immunol; 1997 Jun; 9(3):396-404. PubMed ID: 9203422
[TBL] [Abstract][Full Text] [Related]
70. CTLA-4 is required for the induction of high dose oral tolerance.
Samoilova EB; Horton JL; Zhang H; Khoury SJ; Weiner HL; Chen Y
Int Immunol; 1998 Apr; 10(4):491-8. PubMed ID: 9620605
[TBL] [Abstract][Full Text] [Related]
71. Mutational analysis and an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C-like domain.
Guo Y; Wu Y; Zhao M; Kong XP; Liu Y
J Exp Med; 1995 Apr; 181(4):1345-55. PubMed ID: 7535334
[TBL] [Abstract][Full Text] [Related]
72. Structure of murine CTLA-4 and its role in modulating T cell responsiveness.
Ostrov DA; Shi W; Schwartz JC; Almo SC; Nathenson SG
Science; 2000 Oct; 290(5492):816-9. PubMed ID: 11052947
[TBL] [Abstract][Full Text] [Related]
73. Expression of CD28, CTLA4, CD80, and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy.
Sfikakis PP; Via CS
Clin Immunol Immunopathol; 1997 Jun; 83(3):195-8. PubMed ID: 9175907
[No Abstract] [Full Text] [Related]
74. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.
Freeman GJ; Borriello F; Hodes RJ; Reiser H; Gribben JG; Ng JW; Kim J; Goldberg JM; Hathcock K; Laszlo G
J Exp Med; 1993 Dec; 178(6):2185-92. PubMed ID: 7504059
[TBL] [Abstract][Full Text] [Related]
75. Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.
Fargeas CA; Truneh A; Reddy M; Hurle M; Sweet R; Sékaly RP
J Exp Med; 1995 Sep; 182(3):667-75. PubMed ID: 7544393
[TBL] [Abstract][Full Text] [Related]
76. The radiation-sensitive costimulatory factors involved in B-cell-dependent T-cell activation by minor lymphocyte stimulating antigen.
Chow K; Fu J; Kong H; Jiang S; Chang KS; Shih CC
J Biomed Sci; 1998; 5(5):332-42. PubMed ID: 9758907
[No Abstract] [Full Text] [Related]
77. Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection.
Dong VM; Yuan X; Coito AJ; Waaga AM; Sayegh MH; Chandraker A
Transplantation; 2002 Apr; 73(8):1310-7. PubMed ID: 11981427
[TBL] [Abstract][Full Text] [Related]
78. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
Hurwitz AA; Yu TF; Leach DR; Allison JP
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10067-71. PubMed ID: 9707601
[TBL] [Abstract][Full Text] [Related]
79. Expression of both B7-1 and CD28 contributes to the IL-2 responsiveness of CTLL-2 cells.
Belani R; Weiner GJ
Immunology; 1996 Feb; 87(2):271-4. PubMed ID: 8698390
[TBL] [Abstract][Full Text] [Related]
80. Detection of a soluble form of B7-1 (CD80) in synovial fluid from patients with arthritis using monoclonal antibodies against distinct epitopes of human B7-1.
McHugh RS; Ratnoff WD; Gilmartin R; Sell KW; Selvaraj P
Clin Immunol Immunopathol; 1998 Apr; 87(1):50-9. PubMed ID: 9576010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
